TNFRSF10B and Cowden syndrome 1: A study using the recombinant agonist Apo2L/TRAIL (dulanermin) for the dual proapoptotic receptor DR4/DR5 showed strong and long-lasting antitumor activity in a metastatic CS patient [92], but rapid clearance and decoy receptor binding limited its efficacy.